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Abstract Over the past few decades, research on Alzhei-
mer’s disease (AD) has focused on pathomechanisms
linked to two of the major pathological hallmarks of
extracellular deposition of beta-amyloid peptides and intra-
neuronal formation of neurofibrils. Recently, a third dis-
ease component, the neuroinflammatory reaction mediated
by cerebral innate immune cells, has entered the spotlight,
prompted by findings from genetic, pre-clinical, and clin-
ical studies. Various proteins that arise during
neurodegeneration, including beta-amyloid, tau, heat shock
proteins, and chromogranin, among others, act as danger-
associated molecular patterns, that—upon engagement of
pattern recognition receptors—induce inflammatory sig-
naling pathways and ultimately lead to the production and
release of immune mediators. These may have beneficial
effects but ultimately compromise neuronal function and
cause cell death. The current review, assembled by par-
ticipants of the Chiclana Summer School on
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Neuroinflammation 2016, provides an overview of our
current understanding of AD-related immune processes.
We describe the principal cellular and molecular players in
inflammation as they pertain to AD, examine modifying
factors, and discuss potential future therapeutic targets.
Key Points
Neuroinflammation plays an important part in the
pathogenesis of Alzheimer’s disease (AD), with both
positive and negative consequences.
Induction of inflammatory signaling pathways leads
to the production and release of immune mediators,
which ultimately compromises neuronal function
and causes cell death.
Anti-inflammatory therapeutic approaches to modify
AD progression are the basis for ongoing and future
therapeutic trials in this area.
1 Introduction
Dementias and related diseases of cognitive decline pose
an enormous and growing disease burden on our societies
and health economies. According to the most recent World
Health Organization (WHO) global disease burden report
[1], deaths from neurological diseases have risen by 114%
over the past 20 years to 1.2 million in 2010. The increase
is largely driven by neurodegenerative diseases such as
Alzheimer’s disease (AD) and Parkinson’s disease and by
an aging population in general. Not surprisingly, the
development of strategies to curb this frightening surge is a
high priority for life science research. The responsible
allocation of these resources requires the identification of
valid therapeutic targets. The immune system is particu-
larly alluring in this regard.
How the immune system and peripheral infections
contribute to cognitive decline remains incompletely
understood, but the past 15 years have established a key
role for inflammation in the progression of age-related
neurodegeneration. The immune privilege of the brain is
clearly not absolute, and cells of the central nervous system
(CNS) are sensitive to inflammatory events occurring both
within and outside of the brain.
We summarize the current state of neuroinflammation
research from cellular to molecular mechanisms, as they
pertain to the pathogenesis of AD. Further, we outline
leverage points for preventive strategies and therapeutic
approaches to stem the daunting surge in dementia diseases
facing our society.
2 Cellular Players
2.1 Microglia
Microglia are the principal innate immune cells in the
brain, and they are often considered the macrophages of the
CNS. Recent studies have shed light on their origin from
erythromyeloid progenitors from the yolk sac [2, 3], which
migrate into the brain at embryonic day 7.5 where they
further differentiate into microglial cells [2]. Microglia
exhibit the capacity of self-renewal within the brain [4, 5],
likely arising from a newly identified progenitor [6].
Microglia continuously survey their microenvironment and
monitor ongoing synaptic activity, including synapse
remodeling, debris clearance, and trophic support for
neurons. In addition, they drive a major part of the innate
immune response. Microglia react to pathological triggers
via pathogen-associated molecular patterns (PAMPs) or
danger-associated molecular patterns (DAMPs) [7–9].
Microglia are also phagocytic cells and can ingest
amyloid b (Ab) through a range of cell surface receptors,
including cluster of differentiation (CD)-14, toll-like
receptor (TLR)-2, TLR4, a6b1 integrin, CD47, and scav-
enger receptors, such as CD36 [10–13]. It has been sug-
gested that, in AD, a key factor in the accumulation of Ab
throughout the brain is the failure of microglia to remove
extracellular amyloid [14–16]. Indeed, in cortical tissue
specimens from patients with AD, the microglia sur-
rounding plaques are impaired at Ab uptake [15, 17, 18].
Newly developed positron emission tomography (PET)
techniques employ radio ligands to detect activated
microglia in vivo [19–21]. Many tracers target the 18 kDa
translocator protein (TSPO) [19], an outer mitochondrial
membrane protein present in microglia, which is upregu-
lated during activation [22–24]. The 11C-PK11195 ligand
was the first prototypical TSPO ligand, although second-
generation tracers have been developed more recently with
improved signal-to-noise ratios [25]. However, a common
polymorphism significantly influences the binding affinity
of these new compounds [26], thus making genetic
screening a necessary step for accurate quantification [27].
TSPO upregulation has been described in prodromal AD
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and in manifest AD dementia, using both 11C-PK11195
[28–31] and second-generation tracers [32–36] in regions
known to be affected by AD pathology and beyond. Mixed
evidence has emerged regarding the relationship between
in vivo microglial activation and Ab plaque burden
[29, 31, 32, 37, 38].
2.2 Astrocytes
Under pathological conditions, astrocytes exhibit morpho-
logical changes, including hypertrophy and upregulation of
glial fibrillary acidic protein (GFAP). Astrocytes can detect
aggregated proteins such as Ab or respond to inflammatory
molecules (e.g., cytokines, chemokines, see below).
Indeed, significant astrocyte reactivity has been reported in
sporadic [39–41] and familial AD [42]. Similar to micro-
glia, reactive astrocytes can polarize their processes around
amyloid plaques and are capable of amyloid plaque
degradation [43, 44]. Altered calcium signaling [45],
impaired glutamate homeostasis [46, 47], and increased
production of inflammatory mediators by astrocytes are
also observed in AD.
2.3 Oligodendrocytes
The involvement of oligodendrocytes in AD remains
poorly understood, although there is emerging evidence
that these cells contribute to the pathogenesis and pro-
gression of neurodegenerative disorders, including AD
[48]. Bartzokis et al. [49–52] demonstrated that the loss of
myelin integrity that normally occurs during aging is
strongly aggravated in human presenilin-1 familial, pre-
clinical, and sporadic AD cases, particularly near Ab pla-
ques. In addition, focal loss of oligodendrocytes has been
observed in sporadic cases of AD. This demyelination was
also found in transgenic mouse models of AD, specifically
at the core of Ab plaques [52]. Focal oligodendrocyte loss
has also been detected in Tg2576 and APP/PS1 transgenic
mice [52], a phenomenon that may negatively influence
cortical processing and neurite formation. Several cellular
processes such as neuroinflammation, oxidative stress, and/
or apoptosis may contribute to oligodendrocyte dysfunction
and death [52]. In addition, Ab can impair the survival and
maturation of oligodendrocyte progenitor cells and the
formation of the myelin sheath [53].
2.4 Myeloid Cells Other than Microglia
In addition to microglia, a variety of other monocytic cells
have been found in the brain, including perivascular cells,
meningeal macrophages, choroid plexus macrophages, and
peripheral blood-derived monocytes [54]. These cells may,
under certain circumstances, also phagocytize and degrade
amyloid plaques in a transgenic model of AD [55].
Migration of peripheral monocytes is dependent on C-C
chemokine receptor type 2 (CCR2), as its ablation in
Tg2576 mice results in decreased recruitment of these cells
and a corresponding increase in amyloid pathology [56]. In
contrast, blocking transforming growth factor (TGF)-b
signaling increased peripheral myeloid cell infiltration into
the CNS and significantly reduced the amyloid burden [57].
Glatiramer acetate has also been shown to increase
recruitment of peripheral monocytes to the CNS, and this
reduces amyloid deposition. Ablation of bone marrow-
derived myeloid cells in this model exacerbated amyloid
pathology [58]. In contrast, when resident microglia were
ablated from the APP/PS1 and APP23 mouse models,
recruitment of peripheral myeloid cells was not sufficient
to clear amyloid load [59, 60]. Furthermore, a recent
parabiosis experiment found no evidence of monocyte
infiltration around amyloid plaques [61]. Thus, the extent
of myeloid infiltration into the brain and its contribution to
damage or clearance of pathological proteins is still not
fully understood. A particularly critical aspect of this body
of work is the complexity and toxicity of experimental
approaches used.
3 PAMPs and DAMPs: Inducers and Modulators
of Neuroinflammation in Alzheimer’s Disease
During periods of pathogen invasion or tissue damage,
DAMPs and PAMPs alert the immune system of the host
and trigger an appropriate response to the insult.
DAMPs encompass a diverse class of molecules. A
well-characterized group of DAMPs consists of intracel-
lular proteins that are expressed at a basal level within a
cell and are released after injury. These include high-mo-
bility group protein B1 (HMGB1), S100 proteins, heat
shock proteins (HSPs), chromogranin A, and Ab. A second
class of DAMPs comprises nucleic acids and nucleotide
derivatives, such as mitochondrial DNA (mt-DNA), DNA,
and adenosine triphosphate (ATP) [62]. In contrast,
PAMPs mainly include microbial molecules that are nor-
mally not present in human cells, such as lipid A, flagellin,
lipoproteins from Gram-positive and Gram-negative bac-
teria, bacterial DNA containing particular CpG motifs, and
fragments of bacterial peptidoglycan [63].
Both PAMPs and DAMPs contribute to neuroinflam-
mation in AD. Ab can induce inflammatory responses [64]
via activation of pattern recognition receptors (PRRs) of
the innate immune system, including TLR2 [65], TLR4,
and TLR6, as well as their co-receptors, CD36, CD14, and
CD47. Neutralization by CD14 antibodies can reduce the
Ab-induced microglial activation [66]. Furthermore, the
NLRP1 and NLRP3 inflammasome can sense a range of
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aggregated proteins, including Ab [67]. Indeed, lack of
NLRP3 and caspase-1 has been shown to protect mice from
AD pathology [67, 68].
HMGB1 levels are increased in AD brains and are
associated with senile plaques, promoting their stabiliza-
tion [69]. It has been shown that microglia stimulation by
HMGB1 can reduce Ab phagocytosis [69]. HMGB1 pro-
motes the migration and proliferation of immune cells
through binding to advanced glycation end-product recep-
tors (RAGE) and TLRs [70]. HMGB1 can also act in
concert with other factors such as chemokines, growth
factors, and PAMPs, together promoting immune system
activation [71, 72].
Chromogranin A is associated with microglial activation
in neurodegeneration [73, 74] and induces the release of
interleukin (IL)-1b, indicating that TLRs and the NLRP3
inflammasome are involved in this pathway [75]. In AD,
increased levels of chromogranin A have been observed in
senile plaque dystrophic neurites [76]. Interestingly, the
immune stimulatory potential appears almost identical to
bacterial lipopolysaccharide (LPS), at least in vitro [77].
Many S100 proteins are involved in AD, including
S100A9, S100A8, and S100B. S100A8 and S100A9 form a
complex that is increased in the brain and cerebrospinal
fluid (CSF) of patients with AD [78, 79] and can activate
microglia through TLR4. Furthermore, S100A8-mediated
inflammatory stimuli are connected with the upregulation
of the b-site b-amyloid precursor protein (APP)-cleaving
enzyme BACE1, which is involved in APP processing
[80, 81]. S100B has been observed in both Ab plaques and
in the CSF [82, 83], and overexpression of human S100B
exacerbates amyloidosis and gliosis in the Tg2576 AD
mouse model [84].
Likewise, mt-DNA and DNA can be released from the
cells and act as DAMPs upon entering the blood circula-
tion, causing inflammation [85]. mt-DNA can bind to TLR-
9 and mediate the release of tumor necrosis factor (TNF)-a
and type I interferons (IFNs) [86]. Moreover, cell free
DNA can bind to TLR and non-TLR receptors. Upon TLR
binding, DNA activates the nuclear factor (NF)-jB path-
way, thereby promoting pro-inflammatory cytokine pro-
duction [87]. DNA can also bind to the absent in melanoma
2 (AIM2) inflammasome, releasing IL-1b, through the
caspase-1 activation pathway.
HSPs bind to several receptors, such as TLR2 and
TLR4, resulting in the production of inflammatory
cytokines, such as TNFa and IL-1b [88–90]. Furthermore,
HSPs may also exert beneficial effects in AD, thus, HSP70
can bind to APP and reduce the secretion of Ab1-40 and
Ab1-42 through interference with the APP processing
pathway [91]. HSP70, together with HSP90, can also
interact with tau and Ab oligomers and degrade them by
employing proteasomal degradation [92].
4 Endogenous Modulators
Neurotransmitters such as ATP, glutamate, dopamine, and
various neurotrophic factors, e.g., brain-derived neu-
rotrophic factor (BDNF) and nerve growth factor (NGF),
can act as endogenous modulators. Microglial cells are
equipped with a plethora of neurotransmitter receptors,
which makes them a primary target, particularly as sites of
non-synaptic release [93]. In AD, ATP production from
neurons declines. Mitochondrial dysfunction, as evidenced
by reduced ATP, is related to oxidative stress in AD
pathology [94]. Oxidative stress can also initiate inflam-
matory responses and contributes to the etiopathology of
AD [95].
In AD, glutamatergic neurotransmission is disturbed
because of an increased amount of soluble Ab oligomers
[96]. The possible inflammatory process occurs subse-
quently through activation of microglia with TNFa release,
synergizing with N-methyl-D-aspartate (NMDA)-mediated
neurodegeneration [97]. However, the modulation of glu-
tamate can be either pro- or anti-inflammatory depending
on the expression of different groups of glutamate recep-
tors (GluRs) on microglia and, most likely, on astroglial
uptake capabilities [98, 99].
Dopamine possibly mediates the activation of microglia
by triggering the mitogen-activated protein kinase
(MAPK)–NFjB cascade and inducing toxicity versus
dopaminergic neurons [100, 101]. In general, acetylcholine
prevents the inflammatory response in microglia via a7-
nicotinic acetylcholine receptors, mediated by the PLC/
IP3/Ca2? signaling pathway [102]. In patients with AD,
significant loss of cholinergic neurons is tightly related to
the progression of the disease. Failure in cholinergic neu-
rotransmission decreases the cholinergic input to microglia,
which in turn results in microglial activation [103]. In
addition, stimulation of microglia with norepinephrine
suppressed inflammation through cyclic adenosine
monophosphate (cAMP)/protein kinase A (PKA) signaling
cascades [104, 105]. Of note, the locus ceruleus, the chief
source of noradrenaline (NA) in the human brain, degen-
erates very early in the disease course. Thus, its projection
regions, most prominently the limbic system and neocor-
tex, experience decreased levels of NA. Modeling this in
rodents increased Ab-induced inflammation [106, 107] and
substantially increased neuronal death and memory deficits
[108]. Using 2-photon laser microscopy, it was demon-
strated that depletion of NA in APP/PS1 transgenic mice
caused complete inhibition of microglial Ab clearance,
and, subsequently, an increase in the number and volume
of Ab deposits [104]. The replenishment of NA levels in
the cortex and hippocampal after treatment with L-threo-
DOPS, an NA precursor, partly rescued this phenotype.
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The levels of BDNF and NGF are severely altered in the
brains of patients with AD. BDNF is released by activated
microglia and inhibits the release of TNF-a and IFN-c,
whereas it promotes the expression of anti-inflammatory
cytokines IL-4, IL-10, and IL-11 [109]. However, an
in vitro study has also shown prolonged microglial acti-
vation through a positive feedback loop by autocrine
BDNF [110], demonstrating that BDNF may modulate
inflammation at various levels. In addition, evidence from a
human microglial cell line suggested that NGF synthesis is
potentially stimulated by inflammatory signals (cytokines
and complement factors), as well as by exposure to Ab25-
35, through NFjB-dependent and -independent
mechanisms.
5 Inflammatory Mediators
5.1 Cytokines
Cytokines are released by glial cells, such as astrocytes and
microglia, upon every inflammatory challenge [111–113].
Many cytokines, such as IL-1b and IL-12, have been
related to the progression of AD pathology [114, 115].
Increased IL-1b serum levels have been linked to AD and
patients with mild cognitive impairment, a putative pro-
dromal phase of dementia [114, 116]. Several studies have
reported associations between IL-1b polymorphisms and
the onset of AD pathology [115, 117, 118], linking both IL-
1b polymorphisms and apolipoprotein E (APOE)-e4 to
higher levels of IL-1b in the blood and sleep disturbance in
patients [119]. IL-12 is related to the regulation of the
adaptive and the innate immune system [120], and an IL-12
polymorphism has been linked to AD in a Han Chinese
population [121]. Vom Berg et al. [122] suggested that
inhibition of the IL-12/IL-23 pathway may attenuate AD
pathology and cognitive deficits due to a decrease in the IL-
12p40 subunit and its receptor activity [122]. In this study,
the concentration of IL-12p40 was increased in the CSF of
patients with AD. Regarding anti-inflammatory cytokines,
IL-10 deletion attenuated AD-related deficits, such as
altered synaptic integrity and behavioral deficits in APP/
PS1 mice [123]. Chakrabarty et al. [124] showed that the
overexpression of IL-10 using adeno-associated viruses
(AAVs) increased amyloid deposition, behavioral deficits,
and synaptic alterations and impaired microglial phago-
cytosis of Ab in the APP transgenic mouse model [124].
Another major regulator of inflammation is TGF-b.
Increased TGF-b has been observed in amyloid plaques
[125] and in the CSF of patients with AD [126, 127].
However, this cytokine plays a dual role in AD. Overex-
pression of TGF-b in vivo induces Ab deposition in cere-
bral blood vessels, but it may also decrease microgliosis
while increasing Ab phagocytosis [128]. A link between
TGF-b and neuro-fibrillary tangles (NFTs) has also been
reported [129].
5.2 Chemokines
Chemokines participate in the chemoattraction of immune
cells from the periphery to the brain and in the recruitment
and activation of resident glial cells. In AD, chemokines
are implicated in both the resolution and the propagation of
pathology [130]. The most intensively studied chemokines
in AD are CX3C chemokine ligand 1 (CX3CL1) and
chemokine ligand 2 (CCL2).
CX3CL1, also termed fractalkine, is expressed by neu-
rons, whereas its receptor, CX3CR1, is predominantly
expressed by microglia [131, 132]. The participation of this
chemokine in the pathophysiology of AD is complex since
CX3CL1/CX3CR1 signaling can have a beneficial role in
the context of tau pathology [132–135] or a detrimental
role in an amyloid context [136]. In fact, in an amyloid
model, deficiency of CX3CR1 decreased Ab deposition
[136] but worsened tau pathology and lowered cognitive
performance [133, 134]. Moreover, the expression of
CX3CL1 has been shown to be increased in tau-injured
neurons but decreased in the brains of APP transgenic mice
[137]. However, in human patients, the level of CX3CL1 is
inversely correlated with AD severity [138]. Together, this
may point to the possibility that the same inflammatory
mediator may adopt various, if not opposing, effects and
properties during disease progression.
CCL2 has also been associated with a dominant role in
chronic inflammation [139]. A recent study has demon-
strated that the CCL2/CCR2 pathway of astrocyte-induced
microglial activation is associated with ‘‘M1-polarised’’
and enhanced microglial activity [140]. In AD, CCL2
levels were increased in mild but not in severe AD, sug-
gesting that elevated CCL2 may play a pathogenic role
during early AD stages [141]. In agreement with this,
Westin et al. [142] showed that CCL2 is associated with a
faster cognitive decline in early disease stages. Kiyota et al.
[143] found accelerated neurodegeneration in APP/CCL2
transgenic mice, indirectly suggesting that direct inhibition
of CCL2 signaling may modify microglial activation,
resulting in lower Ab deposition and improving behavioral
outcomes. CCL2 overexpression accelerated oligomeric
and diffuse Ab deposition and led to spatial and working
memory deficits by affecting Ab seeding in Tg2576 mice
[143].
5.3 Other Mediators
Nitric oxide (NO) is synthesized by three different isoforms
of NO synthase (NOS). Each isoform plays a role in either
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AD progression or prevention, suggesting that NO can be
neuroprotective or neurotoxic. High doses of LPS induced
robust CNS inflammation and microglia-induced release of
NO. NO in the CNS can influence many signaling path-
ways, including protein nitrosylation, impairment of long-
term potentiation, or inhibition of mitochondrial respira-
tion. The impact of NO signaling depends on the local
cellular environment. In the AD brain, NO mainly derives
from the inducible isoform of NOS, NOS2, which is
expressed by neurons [144], microglia, and astrocytes
[145]. Nitrosative stress has been shown to affect all types
of cellular proteins, including, but not restricted to,
synaptic proteins. Post-translational protein modification
can take place either by s-nitrosylation of cysteine residues
or by nitration of tyrosine residues. Importantly, Ab itself
represents a nitration target at tyrosine 10 of its amino acid
sequence. Nitration at this position strongly increases the
peptide’s propensity to aggregate, and nitrated Ab pre-
dominantly resides in the core of the deposits, suggesting
that this mechanism contributes to the initiation of depo-
sition [146].
6 Effect of Neuroinflammation on Neuronal
Function
6.1 Cytokines and Synaptic Scaling
Synaptic plasticity is strongly influenced by basal levels of
cytokines [147]. Emblematic is the case of ‘‘synaptic
scaling,’’ a well-defined form of homeostatic plasticity that
regulates the density of GluRs at presynaptic and postsy-
naptic sites [148]. A homeostatic reduction of neuronal
excitability by withdrawal of GluRs is termed down-scal-
ing, whereas the increase of neuronal excitability (by
accumulation of GluRs) is known as up-scaling. TNFa has
been shown to support synaptic up-scaling by increasing
AMPA receptor-dependent miniature excitatory postsy-
naptic currents (mEPSC). Importantly, TNFa required for
up-scaling synapses is derived from glial cells [149] and
not from neurons themselves. Such evidence implies that
glial cells are able to release cytokines in response to
changes in neuronal activity. By contrast, enhanced release
of inflammatory cytokines, for instance during chronic
peripheral inflammation, can disrupt the physiological
mechanisms of synaptic plasticity, promoting neuronal
hyper-excitability and increased susceptibility to seizure
generation [150].
A growing body of evidence demonstrates that micro-
glia can actively respond to increased neuronal excitability,
and microglial processes make physical contact with
excitatory synapses [151–154]. This type of microglia–
synapse interaction has been shown to reduce neuronal
excitability [110, 155], potentially as a form of a regulatory
mechanism for preventing glutamatergic excitotoxicity
[152].
6.2 Microglia and Synaptic Pruning
Microglia can actively participate in remodeling synaptic
connections (‘‘synaptic pruning’’). A pathological form of
synaptic pruning may represent a commonly shared
mechanism among several neurological conditions of dif-
ferent nature: a recent study in a murine model of chronic
stress, showed electron-dense (dark) microglia co-localized
with synaptic terminals. This microglial phenotype asso-
ciated with synaptic pruning appeared clearly reactive,
possibly accounting for an increased loss of synapses
during chronic inflammation [156]. Microglia may also
remove synapses in a complement-dependent manner in a
mouse model of West Nile virus-induced neuroinflamma-
tion [157]. Mice with either a deficit in the number of
microglia (IL-34-/-) or a deficiency of complement com-
ponents (such as C3 protein or complement receptor 3
knock-out) were protected from inflammation-induced
synaptic loss [157].
An alternative hypothesis suggests that pathological
pruning of synapses during inflammation may also repre-
sent a form of ‘‘tissue remodeling’’ for auto-protective
purposes [158]. A study suggested that upon LPS injection,
microglia pruned preferentially GABAergic terminals,
thereby increasing excitatory synaptic activity and induc-
tion of neurotrophic pathways in downstream neurons. This
mechanism has been interpreted as an attempt to promote
neuronal viability in a pathological context, although the
price was a temporary imbalance of synaptic connectivity
[159].
In mouse models of Ab deposition, complement protein
C1q was elevated as early as 1 month of age in both DG
and frontal cortex. At this timepoint, neither plaques nor
synaptic loss are detectable. At a later age (mice aged
3–4 months), the number of synapses decreased signifi-
cantly; however, synaptic loss was rescued almost com-
pletely in the absence of either C1q, C3, or CR3.
Additionally, intracerebroventricular (ICV) injection of
oligomeric Ab in wild-type mice induced synapse loss and
activated a phagocytic phenotype in microglia. Moreover,
synapse loss in response to oligomeric Ab was not
observed in C1q or CR3 knock-out mice [160] (Table 1).
Similar findings have been obtained in a mouse model
deficient for the progranulin gene, typically associated
with frontotemporal dementia (FTD) in humans [161, 162].
Lack of progranulin has been shown to trigger an exag-
gerated inflammatory reaction in microglia and macro-
phages [161, 163]. Interestingly, the brains of progranulin-
deficient mice showed increased levels of complement
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proteins, a prominent pro-phagocytic activation of micro-
glia, and enhanced pruning of synapses [164].
6.3 Inflammation and Neurogenesis
Under homeostasis, immunological signals can actively
shape adult neurogenesis. Microglia were shown to rapidly
engulf and remove apoptotic neuronal progenitors,
remarkably, without any trace of inflammatory reaction
[165, 166]. Other evidence has pinpointed a close interplay
between different immune proteins and the neurogenic
process [167, 168]. IL-1b has often received particular
attention because of its anti-neurogenic activity [169–175].
One may assume that microglia are primarily responsible
for this reduction of neurogenesis during inflammatory
challenges. An interesting molecular player is the CX3C
axis between neurons and microglia, which is known to
preserve the microglial ‘‘resting’’ phenotype under physi-
ological conditions [176, 177]. Several consistent findings
showed reduced neurogenesis in CX3CR1-deficient mice,
along with increased NF-jB activation and IL-1b expres-
sion in microglia [178–181]. Consistently, when an
inflammatory challenge is applied under CX3CR1-deficient
conditions, microglia release an increased and uncontrolled
Table 1 Randomized clinical trials of non-steroidal anti-inflammatory drugs in patients with Alzheimer’s disease
Drug Trial details
(phase, design,
duration of
treatment)
Participants Primary endpoint (s) Main effect References
Aspirin 75 mg od Phase III,
randomized
open-label,
3 years
310 AD pts MMSE and BADLs No effect on cognition,
increased risk of bleeds
[388]
Indomethacin 100–150 mg
od vs. PL
Pilot study,
randomized
1:1, 6 months
28 AD dementia
pts
Psychometric tests Positive effects on a battery of
psychometric tests
[357]
Indomethacin 100 mg od
with omeprazole vs. PL
Pilot study,
randomized
1:1, 1 year
51 pts with mild-
to-moderate
AD
ADAS-cog score Not significant effect on ADAS-
cog score
[389]
Naproxen sodium or
rofecoxib 220 mg
naproxen bid or
rofecoxib 25 mg od vs.
PL
Phase III,
randomized
1:1, 1 year
351 pts with
mild-to-
moderate AD
ADAS-cog score Not significant effect on ADAS-
cog score
[390]
Nimesulide 100 mg bid vs.
PL
Pilot study,
randomized 1:1
and open-label,
3 months
40 AD dementia
pts
Tolerability and short-
term cognitive/
behavioral effects
Not apparent effect on a
composite of cognitive,
behavioral and functional
outcomes
[391]
Rofecoxib 25 mg od vs. PL Phase III,
randomized
1:1, 4 years
1457 MCI pts Annual AD diagnosis Lower annual AD diagnosis but
no significant effect on
ADAS-cog score
[392, 393]
Celecoxib or naproxen
sodium 100 mg bid or
naproxen sodium 220 mg
bid vs. PL
Phase III,
randomized
1:1:1.5,
1–3 years
2528 healthy
individuals
with family
history of AD
Seven tests of cognitive
function and a global
summary score
measured annually
Not significant effect on a
battery of neuropsychological
tests
[394]
ADAPT
study
Celecoxib or naproxen
sodium, follow-up
ADAPT study
2–4 years
follow-up after
termination of
treatment
2071
participants
randomized in
ADAPT
Incidence of AD Not significant effect for
celecoxib. Reduced AD onset
and CSF tau to Ab1-42 ratio
for naproxen
[358]
Celecoxib or naproxen
sodium follow-up
5–7 years
follow-up after
termination of
treatment
1537
participants
randomized in
ADAPT
Cognitive evaluation test
scores
Not significant delay on onset of
AD
[395]
AD Alzheimer’s disease, ADAPT Alzheimer’s Disease Anti-inflammatory, ADAS-cog Alzheimer Disease Assessment Scale-cognitive portion,
BADLs basic activities of daily living, bid twice daily, CSF cerebrospinal fluid, MCI mild cognitive impairment, MMSE Mini-Mental State
Examination, od once daily, PL placebo, pt(s) patient(s)
Adapted from Heneka et al. [396]
Neuroinflammation in Alzheimer’s Disease 1063
amount of inflammatory mediators and free radicals,
causing neurotoxicity and cognitive/behavioral deficits
[132, 182]. Interestingly, during ageing, neurons decrease
expression of CX3CL1 [183], which likely would result in
a general downregulation of the CX3C axis and pro-in-
flammatory skewing of microglia [184, 185]. Pro-inflam-
matory microglial priming has been suggested as a possible
mechanism leading to the dysregulated microglial function
and the ensuing stepwise decline of neurogenesis (and
potentially neurodegeneration) during senility [186–192].
In contrast, several lines of evidence point towards the pro-
neurogenic function of microglia, especially during the
period of early brain development. These indications sug-
gest that microglia play an important role during brain
development, axonal guidance, and formation of neuronal
networks.
6.4 Astrocytes and Glutamate Reuptake
In the CNS, extracellular levels of glutamate are tightly
regulated by astrocytes in order to modulate GluR activity
and prevent potential excitotoxicity [193]. Once in the
synaptic cleft, excess glutamate is promptly scavenged by
the excitatory amino acid transporters (EAATs) expressed
on both neurons and astrocytes [194]. The astrocytic
EAAT2 is thought to be responsible for about 90% of all
glutamate uptake in the brain [195, 196]. There are no
synaptic enzymes that otherwise would degrade glutamate.
Therefore, astrocyte-mediated glutamate uptake represents
the primary mechanism for the homeostatic regulation of
glutamate bioavailability [197]. Impairment of glutamate
uptake causes excitotoxicity characterized by overload of
cellular calcium, generation of free radicals, and protein/
lipid oxidation. Notably, astrocyte glutamate transporters
(EAAT1 and EAAT2) were shown to be reduced in the
cortex and hippocampus of patients with AD [46, 198].
Moreover, Ab-induced neurotoxicity in vivo has been
associated with NMDA receptor-dependent excitotoxicity
[199]. In conclusion, pharmaceutical compounds aiming to
modulate glutamate excitotoxicity have revealed a certain
therapeutic potential for neurodegenerative diseases
(Table 2).
6.5 Function and Dysfunction of the Blood–Brain
Barrier
Dysfunction of the blood–brain barrier (BBB) is a rela-
tively new frontier in AD research [200–202]. The fully
functional BBB is a highly specialized monolayer of
endothelial cells lining the cerebrovasculature and sepa-
rating the circulating blood from the brain parenchyma.
The integrity of the BBB depends critically on the func-
tional state of the associated pericytes, astrocytes, and
microglia and is compromised during neuroinflammation
[203]. Ab binds to low-density lipoprotein receptor-related
protein-1 (LPR1) on the endothelial cells of the brain
capillaries and is then released into the bloodstream
[204, 205]. Vice versa, in the BBB, RAGE are upregulated
with aging and facilitate the influx of Ab from the blood
into the brain [206]. Deficient Ab clearance from the brain
parenchyma is thus proposed to be, at least in part, the
result of its faulty transport across the BBB [207–209].
7 Modifiable Risk Factors for AD
A plethora of exogenous factors exert both beneficial and
detrimental modulating effects on the inflammatory state of
an organism. This, in turn, has direct and important con-
sequences for the risk of developing AD. As these factors
are amenable to non-pharmacological interventions and
can be mitigated (or promoted) by preventive measures or
lifestyle choices, they deserve special attention.
7.1 Infections
The evidence pointing to infections as risk factors for AD
stems from epidemiological and neuropathological studies.
Prospective cohort studies show that infection represents an
important risk factor in the progression of dementia and
AD [210, 211]. A case–control study suggested that mul-
tiple infections double the risk of developing dementia
[212]. In studies of a large AD patient cohort, peripheral
infection was associated with accelerated cognitive decline
[213, 214]. Conversely, the frequency of various infections,
including urinary and respiratory tract infections is higher
among individuals with AD than among healthy, age-
matched controls [215]. Indeed, pneumonia is one of the
most common causes of death in AD [204, 205, 216–218].
In contrast, vaccination against influenza and other infec-
tious conditions is associated with a significantly lower risk
of developing AD [219, 220].
A number of specific viral, bacterial, and fungal infec-
tions has been detected by polymerase chain reaction
(PCR) in human AD brain tissue and have been implicated
in AD development. One example is herpes simplex virus
type 1 (HSV-1) [221–223], which is an AD risk factor in
people carrying the APOE4 allele [224, 225]. Chlamydia
pneumonia, a Gram-negative bacteria, has been detected
via PCR in the brain tissue of patients with AD [226, 227],
where it was found to have infected microglia, astrocytes,
and neurons [227]. Interestingly, fungal proteins and DNA
have been identified in the brain tissue and CSF of patients
with AD [228, 229]. In postmortem AD brains, co-infec-
tion with many fungi has also been reported, with fungal
material identified inside neuronal cells and in many
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Table 2 Clinical trials of non-non-steroidal anti-inflammatory drugs in patients with Alzheimer’s disease
Drug and dosage
regimen
Trial details
(phase, design,
duration of
treatment)
Participants Primary endpoint (s) Main effect Reference
PPARc antagonists
RSG 2, 4, or
8 mg od vs. PL
Phase III, ran 1:1,
24 wk
511 pts mild-to-
moderate AD
ADAS-Cog and CIBIC? in
ITT population
Significant interaction
between APOEe4 allele
status and ADAS-cog.
Significant improvement in
ADAS-cog in APOEe4-
negative pts on RSG 8 mg
[371]
PIO 15–30 mg
od
Pilot study, ran, ol,
6 mo
42 pts mild AD rCBF and plasma levels of
Ab40 and Ab42
Improved cognition and rCBF
in parietal lobe
[367]
PIO 45 mg od
vs. PL, and Vit.
E 200 IU od
Pilot study, ran
1:1, 18 mo
25 pts probable AD Frequency of reported AEs Principal AE was peripheral
edema (28.6% PIO vs. 0%
PL)
[369]
PIO Pro cohort study, 6
y
145,928 subjects
agedC 60 y
Long-term use of PIO
reduced dementia risk by
47%
[368]
RSG od PL, 2 or
8 mg RSG XR
or DON 10 mg
(control)
Phase III, ran 1:1,
24 wk
639 pts probable AD Change in ADAS-Cog score
and CIBIC?
Significant difference
CIBIC?. Peripheral edema
was the most common AE
for RSG XR 8 mg (15%)
[397]
RSG 4 mg od
vs. PL
Pilot study, ran
1:1, 6 mo
30 subjects mild AD or
amnestic MCI
Cognitive performance and
plasma Ab levels
Better delayed recall (at 4 and
6 mo) and selective
attention (6 mo)
[370]
RSG 2 or 8 mg
od
Phase III, ran 1:1
48 wk
2981 pts mild-to-
moderate AD
Change from baseline in
ADAS-cog and CDR-SB
scores
Relevant differences between
treatment groups
[398]
TNFa inhibitors
Perispinal ETA
25–50 mg ow
pro, single-center,
ol, pilot (proof-
of-concept)
study, 6 mo
15 pts mild-to-severe
AD
MMSE, ADAS-cog, SIB Significant improvement by
all primary efficacy
variables
[373]
Perispinal ETA
25–50 mg ow
pro, single-center,
ol, pilot study, 6
mo
12 pts mild-to-severe
AD
California Verbal Learning
Test-Second Edition, Adult
Version; WMS-LM-II,
TMT; Boston Naming Test
FAS, and category verbal
fluency
Significant improvement by
all primary efficacy
variables except Boston
Naming Test
[372]
SC ETA 50 mg
ow
Pilot study, ran
1:1, 24 wk
41 pts mild to moderate
AD
Cognition, global function,
behavior, systemic cytokine
levels
Trends but no statistically
significant changes in
cognition, behavior, or
global function
[399]
Microglia inhibitor
ITA (CHF5074;
CSP1103) 200,
400 or 600 mg
od or PL
Pilot study, ran
1:1, pg,
ascending dose,
12 wk
96 pts MCI Vital signs, cardiac safety,
neuropsychological
performance, safety clinical
laboratory parameters
sCD40L and TNFa in CSF
inversely related to
CHF5074 dose. Plasma
levels of sCD40L with
600 mg/day significantly
lower. Positive dose–
response trend was found on
executive function in
APOE4
[400]
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Table 2 continued
Drug and dosage
regimen
Trial details
(phase, design,
duration of
treatment)
Participants Primary endpoint (s) Main effect Reference
MAPKa
Neflamapimod
(VX745)
NA https://
clinicaltrials.
gov/
(NCT02423122;
NCT02423200)
Cytokines, Ab,
phospho-tau,
neurofilament light
chain and
butyrylcholinesterase
in CFS, and
fludeoxyglucose PET
Treatment effects on
immediate and delayed
recall aspects of episodic
memory
Other agents
PRE 20 mg od
for 4 wk,
maintenance
dose 10 mg od
vs. PL
Phase II, ran 1:1,
1 year
138 pts AD ADAS-cog No change in ADAS-cog
score
[374]
HYD
200–400 mg od
by body weight
vs. PL
Phase II, ran 1:1,
18 mo
168 pts mild AD ADL, cognitive function,
behavioral abnormalities
Any specific subgroup
benefited from
hydroxychloroquine
[378]
SIM up to
80 mg as
tolerated vs. PL
Pilot study, ran
1:1, 26 wk
44 pts AD CSF biomarkers Ab1–40 and
Ab1–42
Significantly decreased
Ab1–40 in mild AD
[376]
ATO 80 mg od
vs. PL
Pilot study, ran
1:1, 1 y
67 pts mild AD ADAS-cog, CGI LOCF
analysis
Significant change in the
scales
[377]
ATO 80 mg od
vs. PL
Phase III, ran 1:1,
72 wk
640 pts mild-to
moderate AD (MMSE
13–25)
ADAS-cog, CGI (co-
primaries)
Not associated with
significant clinical benefit
[375]
IV Ig 0.2 or
0.4 g/kg q2w
vs. PL
Phase III, ran 1:1,
18 mo
390 subjects mild to
moderate AD
ADCS-AD No beneficial effects [401]
TRI 900 mg od
vs. PL
Phase II, ran 1:1,
18 mo
257 amnestic MCI ADAS-cog, conversion to
dementia
Significantly lower rate of
conversion to dementia
[402]
OFA 2.3 g Pilot study, ran
1:1, 6 mo
35 pts mild AD sIL-1RII and Ab1–42 in CSF Influence on inflammatory or
biomarkers in CSF or
plasma
[403]
CIL 100 mg od
vs. control
(ASA 100 mg
or CLO
50–75 mg od)
Pilot study, ran
1:1, 6 mo
20 pts AD and CVD ADAS-cog, Wechsler
Memory Scale, TMT-A
Preventive effect on cognitive
decline
[404]
HG-CSF 5-day
schedule vs. PL
Pilot (proof-of-
concept) study,
ran 1:1, cross-
over design
8 pts mild to moderate
AD
CANTAB computerized
system
Positive change in
hippocampal-dependent
task of cognitive
performance
[405]
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regions [230, 231]. The significance of these findings
remains uncertain because several factors, including post-
mortem time and handling, must be considered before
conclusions are drawn. In addition, causality is notoriously
difficult to ascertain in these scenarios. Systemic inflam-
mation certainly has an impact on the brain, which is not at
all ‘‘immune privileged,’’ as textbooks still suggest. Thus,
higher rates of cognitive decline have been observed in
patients with AD with acute systemic inflammation [214].
Leaky gut may be one of the drivers of systemic inflam-
mation and is directly related to an imbalance of gut
microbiota [232].
7.2 Traumatic Brain Injury
Traumatic brain injury (TBI) leads to damaged blood
vessels, axons, nerve cells, and glia of the brain in a focal,
multifocal, or diffuse pattern, resulting in impaired brain
function [233, 234]. A single moderate or severe TBI may
increase the risk of developing late-onset AD, whereas
repetitive mild TBI (e.g., through contact sport) is associ-
ated with an elevated risk of chronic traumatic
encephalopathy [235, 236]. Two key meta-analyses of
case–control studies found a significant association
between moderate-severe TBI and AD [237, 238]. Fur-
thermore, human pathological studies evince abnormal
accumulation of AD-related pathological proteins, includ-
ing soluble and insoluble Ab and hyperphosphorylated tau
aggregates, following TBI. This, in turn, is supported by
studies in large animals [239, 240]. Aggregation and
deposition of Ab is accelerated after an acute TBI event,
with changes within a mere 24 h up to 2 months after
injury in animal studies [240–244]. Further, aggregation
and deposition of Ab have been associated with memory
impairments in 3xTg-AD mice [244]. Aberrant tau phos-
phorylation has also been described in several models after
TBI [245–248]. The formation of misfolded Ab and tau
oligomeric seeds triggered by TBI may lead to spreading of
the pathology in a prion-like manner, causing a faster and
more severe onset of the disease [249].
7.3 Smoking
The role of smoking as a modifiable risk factor in AD is
controversial. Some early case–control studies reported
smoking had a beneficial effect on AD [250, 251]. In
contrast, more recent cohort studies without affiliation to
the tobacco industry clearly point towards a deleterious
impact [252, 253]. Meta-analyses of these studies showed
that smoking during a lifetime is associated with at least a
1.7 times higher risk of AD [254]. Although this increase
obviously correlates with smoking intensity and duration
[255], the findings regarding former smoking status are
more heterogeneous. Reitz et al. [252] observed no asso-
ciation between past smoking and AD, whereas Aggarwal
et al. [253] reported a lower risk for former smokers car-
rying the ApoEe4 allele than for those who never smoked.
It is estimated that, today, smoking accounts for 4.7
million AD cases worldwide [256]. Evidence from various
in vitro and in vivo studies suggests that sustained cigarette
Table 2 continued
Drug and dosage
regimen
Trial details
(phase, design,
duration of
treatment)
Participants Primary endpoint (s) Main effect Reference
RES 500 mg od
(escalation by
500 mg
increments
q13w, ending
with 1000 mg
bid)
Phase II, ran 1:1
52-wk
119 pts mild-to
moderate AD
Ab1–40 biomarkers in CSF
and serum, brain volume
CSF Ab40 and plasma Ab40
levels declined more with
PL; brain volume loss
increased
[406]
Aß amyloid beta, AD Alzheimer’s disease, ADAPT Alzheimer’s Disease Anti-inflammatory, ADAS-cog Alzheimer Disease Assessment Scale-
cognitive portion, ADCS-AD Alzheimer’s Disease Cooperative Study-Activities of Daily Living Inventory, ADL activities of daily living, AE
adverse effect, ASA acetylsalicylic acid (aspirin), ATO atorvastatin, bid twice daily, CDR Clinical Dementia Rating, CGI Clinical Global
Impression, CIBIC-? Clinician’s Interview-Based Impression of Change Plus Caregiver Input, CIL cilostazol, CLO clopidogrel, CVD cardio-
vascular, DON donepezil, ETA etanercept, HG-CSF human granulocyte colony-stimulating-factor, HYD hydroxychloroquine, Ig immunoglob-
ulin, ITA itanapraced, ITT intention-to-treat, IV intravenous, LOCF last observation carried forward, MAPK mitogen-activated protein kinase,
MCI mild cognitive impairment, MMSE Mini-Mental State Examination, mo months, od once daily, OFA omega-3 fatty acids, ol open-label, ow
once weekly, pg parallel-group, PIO pioglitazone, PL placebo, PPAR peroxisome proliferator-activated receptor, PRE prednisone, pro
prospective, pt(s) patient(s), qxw every x weeks, ran randomized, rCBF regional cerebral blood flow, RES resveratrol, RSG XR rosiglitazone
extended release, SC subcutaneous, SIB Severe Impairment Battery, SIM simvastatin, TMT Trail Making Test, TNF tumor necrosis factor, TRI
triflusal, Vit. vitamin, wk weeks, WMS-LM-II Logical Memory I and II from the Wechsler Memory Scale-Abbreviated, y year
Adapted from Heneka et al [396] with permission
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smoke exposure facilitates the emergence of regional Ab
and tau pathology [257, 258]. Several possible pathways
are likely to contribute to the development of pathological
AD features in smokers. These include cerebrovascular
dysfunction [259], neuroinflammation [258], and protein
misfolding and aggregation [260, 261], which all may be
triggered by an increase in oxidative stress [262–264].
However, human postmortem studies yielded contradictory
results concerning the link between smoking and AD
neuropathology, as Ab levels were reduced in the brains of
active smoker AD cases compared with never-smoking
patients [265]. Remarkably, nicotine and some related
compounds exert neuroprotective effects in a variety of
model systems [266–268], for example via activation of
nicotinic acetylcholine receptors [269] or direct binding to
Ab fibrils [270].
7.4 Physical Activity
A case–control study showed patients with AD were less
active in midlife [271]. Physical inactivity is accompanied
by several secondary effects, including obesity, metabolic
syndrome, type 2 diabetes mellitus (T2DM), and cardio-
vascular disease [272]. In contrast, regular physical exer-
cise positively influences neurogenesis, brain plasticity,
and metabolic function, reduces levels of pro-inflammatory
cytokines and oxidative stress [273–275], and can alter
disease-related biomarkers in patients with dementia [276].
Thus, it is not surprising that cognitive function and mental
processing speed in elderly people could be significantly
improved with leisure time activities and exercise pro-
grams [256, 277–279]. However, Ku¨ster et al. [280]
showed that a (self-reported) active lifestyle rather than the
exercise itself is associated with a decreased risk of AD.
Whether physical exercise benefits all patient populations
equally remains controversial [276, 281]. Some studies
report a stronger effect of physical activity among APOE4
carriers compared with non-carriers [282–284], whereas
others could not replicate these results [285–287]. Analysis
of different animal models suggests positive effects of
physical exercise on BDNF levels, oxidative stress and
even Ab and tau pathology, resulting in delayed disease
onset and progression [288–291].
7.5 Diet and Obesity
Many specific dietary components have been studied in
relation to AD. In clinical studies, a higher intake of
unsaturated fatty acids, antioxidants, and vitamins B12 and
folate have been associated with a lower risk for AD and
cognitive decline [292–294]. However, the opposite or
even no effect has also been found for these factors
[295–297]. Instead of focusing on individual dietary
components, the effect of overall dietary patterns (which
incorporates nutrient interaction) has been examined,
including the Mediterranean Diet (MeDi) [298], Dietary
Approaches to Stop Hypertension (DASH) [299], and the
Mediterranean-DASH Intervention for Neurodegenerative
Delay (MIND) [300]. These studies point towards diet as
having a protective effect against cognitive decline and
development of AD [299, 301–307].
In contrast, overnutrition can lead to obesity, which in
turn has been associated with AD development. Obesity is
characterized by leptin and insulin resistance, leading to
impaired energy metabolism and chronic inflammation
[308]. This chronic inflammatory status can cause cellular
stress and neurodegeneration and is thought to be the link
between obesity and its adverse effects on cognitive per-
formance and AD development [309–313]. Most impor-
tantly, some of these effects may occur as early as midlife.
Thus, increased body mass index and sagittal abdominal
diameter in men aged 40–45 years has been associated
with an increased risk of AD in later life [314].
7.6 Lifetime Distress
Lifetime frequency of stress exposure is consistently
associated with the incidence of mild cognitive impairment
(MCI) and may increase the risk of late-onset AD
[315–317]. In particular, higher levels of the stress hor-
mone cortisol are associated with an accelerated age-re-
lated decline in cognition [318, 319]. The hypothalamic–
pituitary–adrenal (HPA) axis regulates the release of cor-
tisol in humans or the corresponding corticosterone in
rodents. This system is dysregulated in patients with AD,
with higher cortisol levels found in the blood plasma and
CSF of subjects with AD than in age-matched controls
[318, 320].
Interestingly, exposing rodents to stressful experiences
increases corticosterone levels and glucocorticoid receptor
activation, resulting in aggravation of AD-related neu-
ropathology in various transgenic models [321–326].
Microglia are highly responsive to glucocorticoids, with
abundant glucocorticoid receptor expression levels [327].
Furthermore, glucocorticoids can induce a pro-inflamma-
tory microglial phenotype upon stress, especially following
a secondary inflammatory challenge [328–330].
7.7 Diabetes Mellitus
T2DM affects approximately 370 million people world-
wide, accounting for 90–95% of all patients with diabetes
[331]. The disease is characterized by hyperglycemia,
insulin resistance, and relative lack of insulin [332]. People
with T2DM have a 73% greater risk of developing
dementia [333] and decreased white and grey matter
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volume of the temporal and frontal lobes [334, 335].
Cortical and hippocampal atrophies have also been
observed in diabetic mice (db/db) [336].
Importantly, insulin resistance leads to the generation of
NFTs: decreased activation of protein kinase B in T2DM
results in ineffective inhibition of glycogen synthase kinase
3, thus mediating tau phosphorylation and formation of
NFTs [337, 338]. In addition, insulin levels in patients with
diabetes mean the insulin-degrading enzyme is sequestered
away from Ab, which fosters the accumulation of Ab in the
brain [339, 340]. Patients with T2DM have impaired
immunological defense mechanisms, resulting in frequent
infections, which may contribute to the development of AD
[341]. The concentration of pro-inflammatory cytokines in
the CSF is increased in patients with T2DM [342]; indeed,
chronic sub-acute inflammation can also induce insulin
resistance and cause T2DM [343].
8 Protection by Anti-inflammatory Strategies
8.1 Past and Present Strategies
Various anti-inflammatory therapeutic approaches have
been taken to modify AD progression over the past 2
decades, ranging from non-steroidal anti-inflammatory
drugs (NSAIDs) to TNFa inhibition.
8.1.1 Non-steroidal Anti-inflammatory Drugs (NSAIDs)
One of those approaches was ADAPT (Alzheimer’s Dis-
ease Anti-inflammatory Prevention Trial). This trial was
constructed to examine whether NSAIDs could prevent or
delay the onset of AD and whether such treatment could
impact cognitive decline associated with aging [344].
Early epidemiological studies had suggested that long-
term treatment with NSAIDs decreased the risk of AD
development [345–348]. Additionally, strong experimental
evidence has emerged supporting the positive effect of
NSAIDs in AD animal models [80, 349]. NSAIDs have
been shown to reduce Ab secretion and accumulation, both
in vitro and in vivo, to modulate c-secretase activity, to
exert an anti-inflammatory effect, and to improve cognitive
function in AD mouse models [350–355].
However, most NSAIDs have not convincingly shown
any beneficial effects during clinical trials in patients with
AD [356]. Only a small, early study using indomethacin in
patients with AD [357], which has not been replicated, and
a follow-up analysis from the ADAPT research group using
naproxen [358] have shown positive effects. Aspirin also
did not prove effective against AD but increased the risk of
serious bleeds (AD2000 trial).
8.1.2 Non-NSAIDs
Peroxisome proliferator-activated receptor (PPAR)-c ago-
nism has consistently been shown to reduce the production
of inflammatory cytokines and amyloid accumulation in
AD mouse models [351, 359–362]. Rosiglitazone induces
activation of the ERK pathway, leading to cognitive
enhancement in AD models [363–366]. Pioglitazone has
been found to improve cognition and cerebral blood flow in
mild AD [367]. Additionally, pioglitazone treatment
reduced dementia risk in patients with initially non-insulin-
dependent diabetes mellitus in a case–control study [368].
However, a pilot randomized clinical trial for the safety of
this drug in patients with AD found no significant effect
[369]. Rosiglitazone has been found to delay cognitive
decline in patients with early AD and MCI [370]. Another
study showed improvement in cognitive function using
pioglitazone, which was restricted to APOEe4 non-carriers
[371]. The TOMORRW study is ongoing and will evaluate
the efficacy of pioglitazone versus placebo in delaying the
onset of MCI-AD in cognitively normal participants who
are at high risk for developing MCI within the next 5 years
(NCT01931566).
8.1.3 Tumor Necrosis Factor-a Inhibitors
Inhibiting TNFa signaling has also become an interesting
and promising approach to the treatment of AD. A clinical
case report found that intrathecal administration of inflix-
imab (an antibody against TNFa already approved for
other indications) reduced Ab plaques and tau pathology in
APP/PS1 mice and enhanced cognitive function. Addi-
tionally, two small pilot clinical studies using a different
TNFa inhibitor, etanercept, showed cognitive improvement
in patients with AD [372, 373]. However, these studies
used small sample sizes and an open-label design and
lacked a placebo group. Thus, a larger well-designed pla-
cebo-controlled study would be necessary to assess the
possible utility of TNFa in AD [349].
8.1.4 Other Anti-inflammatory Drugs
Trials have examined other anti-inflammatory drugs, such
as prednisone, hydroxychloroquine, simvastatin, and ator-
vastatin, but have shown no significant positive cognitive
effects in patients with AD [368, 374–378].
8.2 Future Strategies
Recently, fenamate NSAIDs including mefenamic acid
were found to selectively inhibit NLRP3 through the
inhibition of volume-regulated ion channels (VRACs),
thereby preventing cognitive impairments in rodent models
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of AD. Mefenamic acid is already on the market and is
used for abdominal pain in premenstrual syndrome.
MCC950, a new potent NLRP3-selective inhibitor has been
developed but is not yet available for clinical use [379].
Anakinra, an IL-1 receptor antagonist, and a neutralizing
antibody, canakinumab, have been proposed to work by
inhibiting this NLRP3 axis, but the cost benefit and
bioavailability in the brain remains a concern [380].
CSP-1103 (also known as CHF 5074 or Itanapraced) is
now in phase III clinical trials as a microglia modulator. It
may inhibit Ab plaque deposition, reduce tau pathology,
restore normal microglial function by increasing phago-
cytosis, and decrease production of pro-inflammatory
cytokines [381].
Some other new therapeutic targets have been proposed.
MAPKa inhibitors (e.g., Neflamapimod [VX-745]) could
reduce IL-1b levels [382] (NCT02423200). Administration
of low-dose IL-2 could increase plaque-associated micro-
glia and improve cognitive performance [383]. C3aR
antagonist SB290157 could decrease amyloid load and
microgliosis [384]. PD-1 inhibitors could reduce plaque
load and improve cognition [385]. Blocking the p40
common subunit of IL-12 and IL-23 could decrease amy-
loid burden [122, 359, 386]. A CD33 inhibitor might pro-
mote microglial phagocytosis of Ab [387].
9 Summary and Conclusions
Neuroinflammation in AD is likely to arise from the
recognition of Ab by PRRs on the surface of innate
immune cells in the brain. Once initiated, sustained
inflammation and neurodegeneration may unleash further
factors, which, in turn, act as DAMPs and thereby con-
tribute to the persisting and chronic sterile immune reaction
in the brain. Several mechanisms of interaction by which
inflammatory processes contribute to disease progression
have been identified. Given that deposition of Ab occurs
decades prior to the first amnestic and cognitive deficits,
such mechanisms may represent promising therapeutic
targets. Identification of suitable mode and site of inter-
vention models, which better target the human cerebral
innate immune system, and associated biomarkers, is
urgently required.
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